Ethicon Morcellator Hysterectomy Lawsuit

Ethicon Morcellator Hysterectomy Lawsuit
On July 31, 2014, Johnson & Johnson’s Ethicon unit announced a recall of the uterine fibroid morcellator due to the risk of cancer of the uterus.

The nationally-recognized defective medical device lawyers at Nadrich & Cohen, LLP, are actively investigating the claims of women who have suffered cancer resulting complications following a laparoscopic hysterectomy or uterine fibroid removal procedure, where a morcellator was used.

Oftentimes during laparoscopic hysterectomies and removal of uterine fibroids, a powered morcellator was used. The morcellator consists a bladed tube which is placed in the abdomen. The morcellator blade pierces and cuts the uterine tissue into small pieces for easy removal. Morcellator-assisted procedures were marketed by manufacturers as reducing recovery time, lowering the risk of infection, and reduction in incision size.

Ethicon was the largest manufacturer of Uterine Fibroid Power morcellator. The recall occurred after a July 11, 2014, FDA advisory meeting to review the available data that a power morcellator increased the risk and spread of cancer in the uterus. The most common cancers which occur are uterine, pelvic and abdominal cancers.  (leiomyosarcoma or endometrial stromal sarcoma (ESS).

On April 17, 2014, the FDA issued a Safety Communication warning of the risks posed by the use of the morcellator device in laparoscopic hysterectomy or laparoscopic myomectomy procedures. Women that have had a morcellation laparoscopic hysterectomy or myomectomy and also have a diagnosis of Leiomyosarcoma (LMS), are at risk of having the morcellator spread the cancerous tissue throughout the pelvis and abdomen. This complication can cause cancer to become even more aggressive because cancer has been allowed to spread and is no longer contained.

If you or a loved one have had a morcellation laparoscopic hysterectomy or myomectomy and been diagnosed with pelvic cancer, abdominal cancer or Leiomyosarcoma (LMS), you may be entitled to financial compensation for injuries caused by the defective morcellator.

The morcellator has been on the market since 2000. About 60,000 women undergo these procedures yearly. Our lawyers are investigating morcellator complication claims in all 50 states. We are investigating claims, where a patient now has diagnosed cancer of the pelvis, abdomen and underwent one of the following procedures:

  • A. Laparoscopic Myomectomy (uterine fibroid removal);
  • B. Laparoscopic supracervical hysterectomy; or
  • C. Robotic hysterectomy.

To find out if you or a loved one may be entitled to financial compensation for your injuries or loss, call the Defective Medical Device Attorneys of Nadrich & Cohen, LLP at 1-800-718-4658. A member of our Morcellator Injury Team will respond to your request within 12 hours and provide you with a free, confidential claim evaluation. Time is of the essence to make a claim. Contact us now to see if you or a loved one may be entitled to financial compensation for complications related to the morcellation laparoscopic hysterectomy or myomectomy procedure.

We are currently investigating morcellator claims against the following manufacturers:

  • A. Karl Storz
  • B. Ethicon Gynecare
  • C. Blue Endo
  • D. Cook
  • E. Trokamed
  • F. FemRx/Johnson & Johnson
  • G. Gyrus/Olympus
  • H. Nouvag
  • I. LINA Medical

We believe the manufacturers of the morcellation devices knew or should have known of the risks associated with the use of the device, such as the possibility that the morcellator could cause the spread of cancers throughout the abdomen and pelvis. We also believe the manufacturers of these devices may have withheld necessary information from potential users, thereby preventing them from making an informed decision about the risks associated with its use.

Please contact us for a free, confidential claim evaluation, by calling us at 1-800-718-4658.

We are contingency lawyers, which means there are never any out of pocket costs, fees or expenses to you unless we obtain a recovery.